



(51) International Patent Classification:

C07D 403/06 (2006.01) C09B 23/06 (2006.01)
C07D 209/08 (2006.01) G01N 33/00 (2006.01)
C09B 23/02 (2006.01) G01N 33/533 (2006.01)

(21) International Application Number:

PCT/GB2016/052986

(22) International Filing Date:

26 September 2016 (26.09.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1516987.3 25 September 2015 (25.09.2015) GB

(71) Applicant: ILLUMINA CAMBRIDGE LIMITED

[GB/GB]; Chesterford Research Park, Little Chesterford, Essex Cambridgeshire CB10 1XL (GB).

(72) Inventors: FRANCAIS, Antoine; c/o Illumina Cambridge

Limited, Chesterford Research Park, Little Chesterford, Essex Cambridgeshire CB10 1XL (GB). LIU, Xiaohai; c/o Illumina Cambridge Limited, Chesterford Research Park, Little Chesterford, Essex Cambridgeshire CB10 1XL (GB).

(74) Agent: STRATAGEM INTELLECTUAL PROPERTY

MANAGEMENT LIMITED; Meridian Court, Comber-

ton Road, Toft, Cambridge Cambridgeshire CB23 2RY (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: POLYMETHINE COMPOUNDS AND THEIR USE AS FLUORESCENT LABELS




Figure 1

(57) Abstract: The present disclosure relates to new compounds and their use as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

Polymethine Compounds and their use as Fluorescent labels

The present disclosure relates to new polymethine compounds and their use as fluorescent markers. In particular the compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

Background

Several publications and patent documents are referenced in this application in order to more fully describe the state of the art to which this disclosure pertains. The disclosure of each of these publications and documents is incorporated by reference herein.

Non-radioactive detection of nucleic acids utilizing fluorescent labels is an important technology in molecular biology. Many procedures employed in recombinant DNA technology previously relied heavily on the use of nucleotides or polynucleotides radioactively labelled with, for example ^{32}P . Radioactive compounds permit sensitive detection of nucleic acids and other molecules of interest. However, there are serious limitations in the use of radioactive isotopes such as their expense, limited shelf life and more importantly safety considerations. Eliminating the need for radioactive labels enhances safety whilst reducing the environmental impact and costs associated with, for example, reagent disposal. Methods amenable to non-radioactive fluorescent detection include by way of non-limiting example, automated DNA sequencing, hybridization methods, real-time detection of polymerase-chain-reaction products and immunoassays.

For many applications it is desirable to employ multiple spectrally distinguishable fluorescent labels in order to achieve independent detection of a plurality of spatially overlapping analytes. In such multiplex methods the number of reaction vessels may be reduced, simplifying experimental protocols and facilitating the production of application-specific reagent kits. In multi-colour automated DNA sequencing for example, multiplex fluorescent detection allows for the analysis of multiple nucleotide bases in a single electrophoresis lane, thereby increasing throughput over single-colour methods and reducing uncertainties associated with inter-lane electrophoretic mobility variations.

However, multiplex fluorescent detection can be problematic and there are a number of important factors which constrain selection of fluorescent labels. First, it may be difficult to find dye compounds whose emission spectra are suitably spectrally resolved in a given application. In addition when several fluorescent dyes are used together, to generate fluorescence signals in distinguishable spectral regions by simultaneous excitation may be difficult because the absorption bands of the dyes which could be useable for this are usually widely separated, so it is difficult to achieve more or less equal fluorescence excitation efficiency even for two dyes. Many excitation methods use high power light sources like lasers and therefore the dye must have sufficient photo-stability to withstand such excitation. A final consideration of particular importance in molecular biology methods is the extent to which the fluorescent dyes must be compatible with the reagent chemistries used such as for example DNA synthesis

solvents and reagents, buffers, polymerase enzymes and ligase enzymes.

As sequencing technology advances a need has developed
5 for further fluorescent dye compounds, their nucleic acid
conjugates and dye sets which satisfy all of the above
constraints and which are amenable particularly to high
throughput molecular methods such as solid phase
sequencing and the like.

10


Fluorescent dye molecules with improved fluorescence
properties such as fluorescence intensity, shape and
wavelength maximum of fluorescence band can improve the
speed and accuracy of nucleic acid sequencing. Strong
15 fluorescence signal is especially important when
measurements are made in water-based biological buffers
and at higher temperature as the fluorescence intensity
of most dyes is significantly lower at such conditions.
Moreover, the nature of the base to which a dye is
20 attached also affects the fluorescence maximum,
fluorescence intensity and others spectral dye
properties. The sequence specific interactions between
the nucleobases and the fluorescent dyes can be tailored
by specific design of the fluorescent dyes. Optimisation
25 of the structure of the fluorescent dyes can improve the
efficiency of nucleotide incorporation, reduce the level
of sequencing errors and decrease the usage of reagents
in, and therefore the costs of, nucleic acid sequencing.

30 Described herein are improved polymethine constructs and
their use as bio-molecule labels, particularly as labels
for nucleotides used in nucleic acid sequencing.
Particular improvements can be seen in the efficiency of
labelled nucleotide incorporation and length and accuracy

of sequencing read obtainable using the new fluorescent constructs. The molecules described below are particularly advantageous in situations where high power excitation sources are used. High power excitation can result in a degree of power saturation, where the number of photons emitted by the labels ceases to be linear with an increase in excitation power. Power saturation can be caused by molecular quenching effects relating to the structure of the labels, or can be caused by labels having a longer than desired fluorescence lifetime, whereby the labels spend a longer period than desired in the excited state before emitting a photon. Where multiple different labels are used in parallel, having one of the labels reaching power saturation when other labels continue to get brighter makes differentiation of the labels more difficult. Labels described herein are particularly advantageous in reaching power saturation at a higher level than corresponding prior art labelling compounds.

Summary


According to a first aspect this disclosure provides compounds of the formula (I) or mesomeric forms thereof:



(I)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and m is an integer 0-3;
 p is an integer 1-2;
 5 q is an integer 1-5;
 alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;
 Y is S, O or CH₂;
 Z is OH;
 10 n is an integer 0-3;
 X is OH or O⁻ or an amide or ester conjugate thereof;
 each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;
 15 each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl.

P can be one; in which case the compounds are of the formula (Ia) or mesomeric forms thereof:



20

(Ia)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and m is an integer 0-3;
 q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH₂;

Z is OH;


5 n is an integer 0-3;

X is OH or O⁻ or an amide or ester conjugate thereof;

each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;

10 each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl.

P can be two; in which case the compounds are of the formula (Ib) or mesomeric forms thereof:



15

(Ib)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

q is an integer 1-5;

20 alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH₂;

Z is OH;

n is an integer 0-3;

25 X is OH or O⁻ or an amide or ester conjugate thereof;

each of R_{a1} and R_{a2} is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;

each of R_{c1} and R_{c2} is independently alkyl or substituted
5 alkyl.

In certain examples where R_{a1} or R_{a2} is H; either R_{c1} or R_{c2} can be an alkyl sulfonic acid group. The compounds require one or more sulfonic acid substituents, such that
10 at least one of R_{a1} or R_{a2} is SO_3^- , or R_{a1} or R_{a2} is a further ring fused to an adjacent carbon atom, the further ring having an SO_3^- , or R_{c1} or R_{c2} is an alkyl sulfonic acid group.

15 In certain examples where p is 2, R_{c1} or R_{c2} is an alkyl sulfonic acid group.

In certain examples r equals 3.

20 In certain examples n is 1. The OH group may be at the 4-position on the ring. In certain examples n is 0 and the phenyl ring is unsubstituted. In certain examples where n is 0, Y is S or O (and not CH_2).

25 In another embodiment the compounds of the present disclosure can be conjugated with a variety of substrate moieties such as, for example, nucleosides, nucleotides, polynucleotides, polypeptides, carbohydrates, ligands, particles, cells, semi-solid surfaces (e.g. gels) and
30 solid surfaces. The conjugation can be carried out via carboxyl group $C(=O)-X$, which can be turned into an amide or ester.

According to a further aspect of the disclosure therefore, there are provided dye compounds comprising linker groups to enable, for example, covalent attachment to such substrate moieties.

5

According to a further aspect the disclosure provides a nucleoside or nucleotide compound defined by the formula: N-L-Dye, wherein N is a nucleotide, L is an optional linker moiety and Dye is a fluorescent compound according to the present disclosure.

10

In a further aspect the disclosure provides methods of sequencing using the dye compounds of the present disclosure.

15

According to a further aspect the disclosure also provides kits comprising dye compounds (free or in conjugate form) which may be used in various immunological assays, oligonucleotide and nucleic acid labelling and for DNA sequencing by synthesis. In yet another aspect the disclosure provides kits comprising dye `sets` particularly suited to cycles of sequencing by synthesis on an automated instrument platform.

20

A further aspect of the disclosure is the chemical preparation of compounds of the disclosure.

25


Detailed Description

This disclosure provides novel compounds particularly suitable for methods of fluorescence detection and sequencing by synthesis. Compounds having an indole N-phenyl moiety are advantageous in fluorescence intensity, photostability compared to N-alkyl analogues and

30

therefore improve certain nucleic acid sequencing applications.

According to a first aspect the disclosure provides
5 compounds of the formula (I) or mesomeric forms thereof:



(I)

wherein mCat+ or mAn- is an organic or inorganic positively/negatively charged counterion and

10 m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

15 Y is S, O or CH₂;

Z is OH;


n is an integer 0-3;

X is OH or O⁻ or an amide or ester conjugate thereof;

20 each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;

each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl.

The disclosure provides a compound of the formula (I) or mesomeric forms thereof:



(I)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH_2 ;

Z is OH;


n is an integer 0-3;

X is OH or O^- or an amide or ester conjugate thereof;

each of R_{a1} and R_{a2} is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom; and

each of R_{c1} and R_{c2} is independently alkyl or substituted alkyl, wherein at least one of R_{a1} or R_{a2} is SO_3^- , or R_{a1} or R_{a2} is a further ring fused to an adjacent carbon atom, the further ring having an SO_3^- , or R_{c1} or R_{c2} is an alkyl sulfonic acid group.

The disclosure provides a compound of the formula (I) or mesomeric forms thereof:



(I)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

5 p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH₂;

10 Z is OH;

n is an integer 0-3;


X is OH or O⁻ or an amide or ester conjugate thereof;

each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon

15 atom; and

each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl, wherein when n is 0, Y is S or O.

The disclosure provides a compound of the formula (I) or
20 mesomeric forms thereof:



(I)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

5 p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH_2 ;

10 Z is OH;

n is an integer 0-3;

X is OH or O^- or an amide or ester conjugate thereof;

each of Ra_1 and Ra_2 is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon

15 atom; and

each of Rc_1 and Rc_2 is independently alkyl or substituted alkyl, wherein at least one of Ra_1 or Ra_2 is SO_3^- , or Ra_1 or Ra_2 is a further ring fused to an adjacent carbon atom, the further ring having an SO_3^- , or Rc_1 or Rc_2 is an alkyl
20 sulfonic acid group and wherein when n is 0, Y is S or O.

The molecules may contain one or more sulphonamide or SO_3^- moieties at position Ra . Ra_1 and/or Ra_2 may be SO_3^- or sulphonamide. The other Ra (Ra_1 or Ra_2) can be
25 independently H, SO_3^- , sulphonamide, halogen, or a further


ring fused to an adjacent carbon atom. Ra_1 or Ra_2 can be H. Ra_1 or Ra_2 can be SO_3^- . Ra_1 can be different to Ra_2 , for example the structure can have a single sulfonamide group at Ra_1 , and H as Ra_2 . Ra_1 and Ra_2 can both be sulphonamide.

- 5 The sulphonamide can be SO_2NH_2 or SO_2NHR , where R is an alkyl, substituted alkyl, aryl or substituted aryl group. Where neither Ra_1 or Ra_2 is a SO_3^- or a further ring fused to an adjacent carbon atom, then Rc_1 or Rc_2 must be an alkyl sulfonic acid group.

10

Ra_1 or Ra_2 can be a further aliphatic, aromatic or heterocyclic ring fused to adjacent carbons of the indole ring. For example, in such cases when an aromatic ring is fused the dyes end group can represent a structure of


15 type




where Rd can be H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or
20 sulfonic acid.

Thus the dyes of the disclosure can be described by Formula (1C) or (ID) or mesomeric forms thereof:

25



(IC)



(ID)

wherein mCat+ or mAn- is an organic or inorganic positively/negatively charged counterion and

5 m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

10 Y is S, O or CH₂;

Z is OH;

n is an integer 0-3;


X is OH or O⁻ or an amide or ester conjugate thereof;

each of R_{a1} and R_{a2} is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;


each of R_{c1} and R_{c2} is independently alkyl or substituted alkyl; and

R_d is H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or sulfonic acid.

Thus the dyes of the disclosure can be described by Formula (1C) or (1D) or mesomeric forms thereof:



(1C)



(1D)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

p is an integer 1-2;

5 q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH_2 ;

Z is OH;

10 n is an integer 0-3;

X is OH or O^- or an amide or ester conjugate thereof;


each of Ra_1 and Ra_2 is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;

15 each of Rc_1 and Rc_2 is independently alkyl or substituted alkyl; and


Rd is H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or sulfonic acid, wherein at least one of Ra_1 or Ra_2 is SO_3^- , or Rd is SO_3^- ,

20 or Rc_1 or Rc_2 is an alkyl sulfonic acid group.

Thus the dyes of the disclosure can be described by Formula (1C) or (1D) or mesomeric forms thereof:



(IC)



(ID)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

5 m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

10 Y is S, O or CH₂;

Z is OH;

n is an integer 0-3;


X is OH or O⁻ or an amide or ester conjugate thereof;

each of R_{A1} and R_{A2} is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;


each of R_{C1} and R_{C2} is independently alkyl or substituted alkyl; and

R_d is H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or sulfonic acid, wherein when n is 0, Y is S or O.

Thus the dyes of the disclosure can be described by Formula (1C) or (1D) or mesomeric forms thereof:



(1C)



(1D)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

p is an integer 1-2;

5 q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH_2 ;

Z is OH;

10 n is an integer 0-3;

X is OH or O^- or an amide or ester conjugate thereof;

each of Ra_1 and Ra_2 is independently H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;

15 each of Rc_1 and Rc_2 is independently alkyl or substituted alkyl; and

Rd is H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or sulfonic acid, wherein at least one of Ra_1 or Ra_2 is SO_3^- , or Rd is SO_3^- ,

20 or Rc_1 or Rc_2 is an alkyl sulfonic acid group and wherein when n is 0, Y is S or O.

In formula (IC) or (ID) the additional rings fused to adjacent carbon atoms of the indole ring may be
25 optionally substituted, for example with sulfonic acid or sulphonamide.

The $C(=O)-X$ carboxy group or its derivatives is attached to the indole nitrogen atom by an alkyl chain of length
30 q , where q is 1-5 carbon or hetero- atoms. The chain may be $(CH_2)_q$ where q is 1-5. The group may be $(CH_2)_5COOH$.

The molecules can contain one or more alkyl-sulfonate moieties at position Rc . Either Rc_1 and/or Rc_2 may be

alkyl-SO₃⁻. The other Rc (Rc₁ or Rc₂) can be independently alkyl or substituted alkyl. Rc₁ and Rc₂ may be independently methyl, ethyl, propyl, butyl, pentyl, hexyl or (CH₂)_tSO₃H, where t is 1-6. t may be 1-4. t may be 4.


5 Rc₁ and Rc₂ may be a substituted alkyl group. Rc₁ and Rc₂ may contain a COOH or -SO₃H moiety or their ester or amide derivatives.

In certain embodiments, when one of Ra₁ or Ra₂ is SO₃⁻, and
 10 the other of Ra₁ or Ra₂ is H or SO₃⁻, either Rc₁ or Rc₂ can also be an alkyl sulfonic acid group.


The COOH group shown as C(=O)-X can act as a linking moiety for further attachment or is linked to a further
 15 molecule. Once conjugation has occurred, the COOH or COO⁻ is converted into an amide or ester.

Examples of compounds include structures according to formula(II) or (IIa) or mesomeric forms thereof:

20



(II)



(IIa)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and m is an integer 0-3;

5 p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH₂;

10 Z is OH;

n is an integer 0-3;


X is OH or O⁻ or an amide or ester conjugate thereof;

each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon


15 atom; and

each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl.

Examples of compounds include structures according to
20 formula(II) or (IIa) or mesomeric forms thereof:



(II)



(IIa)

wherein mCat+ or mAn- is an organic or inorganic positively/negatively charged counterion and

5 m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

10 Y is S, O or CH₂;

Z is OH;

n is an integer 0-3;


X is OH or O⁻ or an amide or ester conjugate thereof;

each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide,


15 halogen, or a further ring fused to an adjacent carbon atom; and

each of R_{C1} and R_{C2} is independently alkyl or substituted alkyl, wherein when n is 0, Y is S or O.

Further examples of compounds include structures
5 according to formula (IIIa) or (IIIb):



(IIIa)



(IIIb)

wherein $mCat+$ or $mAn-$ is an organic or inorganic positively/negatively charged counterion and

10 m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

15 t is an integer 1-6;

Y is S, O or CH_2 ;

Z is OH;


n is an integer 0-3;

X is OH or O⁻ or an amide or ester conjugate thereof;


each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon atom; and

each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl.

Further examples of compounds include structures according to formula (IIIa) or (IIIb):



(IIIa)



(IIIb)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

t is an integer 1-6;

5 Y is S, O or CH₂;

Z is OH;


n is an integer 0-3;

X is OH or O⁻ or an amide or ester conjugate thereof;




each of Ra₁ and Ra₂ is independently H, SO₃⁻, sulfonamide,
10 halogen, or a further ring fused to an adjacent carbon atom; and

each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl, wherein when n is 0, Y is S or O.

15 Further examples of compounds include structures according to formula (IVa) to (IVd):



(IVa)



5

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and m is an integer 0-3;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH₂;

5 Z is OH;

n is an integer 0-3;

X is OH or O⁻ or an amide or ester conjugate thereof;


Ra₁ is H, SO₃⁻, sulfonamide, halogen, or a further ring fused to an adjacent carbon atom;

10 Rc₁ is alkyl or substituted alkyl; and


Rd is H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or sulfonic acid.

Further examples of compounds include structures


15 according to formula (Va) to (Vd):




(Va)



(Vb)



(Vc)



(Vd)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

q is an integer 1-5;

5 alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;


Y is S, O or CH_2 ;

Z is OH;

n is an integer 0-3; and


10 X is OH or O^- or an amide or ester conjugate thereof.

Further examples of compounds include structures according to formula (VIa) to (VIId):




15


(VIa)



(VIb)



(VIc)



(VIId)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

q is an integer 1-5;

5 alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

t is an integer 1-6;

Y is S, O or CH₂;

Z is OH;

10 n is an integer 0-3; and

X is OH or O⁻ or an amide or ester conjugate thereof.

alk is an alkyl, alkenyl or alkynyl chain of 1-5 carbon atoms optionally containing one or more double or triple

15 bonds. Alk can be a group (CH₂)_r where r is 1-5. Alk can be (CH₂)₃. Alternatively the carbon chain may contain one or more double bonds or triple bonds. The chain may contain a linkage -CH₂-CH=CH-CH₂-, optionally with further CH₂ groups. The chain may contain a linkage -CH₂-C≡C-CH₂-,
20 optionally with further CH₂ groups.

In any of the examples given in formula VII to VIII; r can equal 3.

25 In any of the examples given in formula I to VIII; q can equal 5.

In any of the examples given in formula III, formula VI or formula VII; t can equal 4.

30

In any of the examples given in formula I to VI; n can equal 1-3. In any of the examples given in formula I to VI; n can equal 1. In any of the examples given in formula I to VI; n can be an integer 0-1. Where n is 1,

the OH group can be at any position on the ring. The OH group can be at the 4 position. Where n is 2 or 3, the OH groups can be at any positions on the phenyl ring.


- 5 In any of the examples given in formula I to VI; when n is zero, Y can equal O or S and not CH₂.

In any of the examples given in formula I to VI; Y can equal O.


10

In any of the examples given in formula I to VI; Y can equal O. Where Y is O, n can be 0-3. Where Y is CH₂, n can be 1-3.


- 15 Further examples of compounds include structures according to formula (VIIa) to (VIId):




(VIIa)



(VIIb)



(VIIc)



(VIId)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;


5 q is an integer 1-5;

r is an integer 1-5;


t is an integer 1-6; and

X is OH or O^- or an amide or ester conjugate thereof.


10 Further examples of compounds include structures according to formula (VIIIa) to (VIIId):




(VIIIa)



(VIIIb)



(VIIIc)



(VIIIId)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

5 q is an integer 1-5;

r is an integer 1-5; and

X is OH or O⁻ or an amide or ester conjugate thereof.

A particularly useful compound is a nucleotide or
10 oligonucleotide labelled with a dye as described herein.

The labelled nucleotide or oligonucleotide may have the label attached to the nitrogen atom of indole via an alkyl-carboxy group to form an amide. The labelled
15 nucleotide or oligonucleotide may have the label attached to the C5 position of a pyrimidine base or the C7 position of a 7-deaza purine base through a linker moiety.

20 The labelled nucleotide or oligonucleotide may also have a blocking group covalently attached to the ribose or deoxyribose sugar of the nucleotide. The blocking group may be attached at any position on the ribose or

deoxyribose sugar. In particular embodiments, the blocking group is at the 3' OH position of the ribose or deoxyribose sugar of the nucleotide.

5 Provided herein are kits including two or more nucleotides wherein at least one nucleotide is a nucleotide labelled with a compound of the present disclosure. The kit may include two or more labelled nucleotides. The nucleotides may be labelled with two or
10 more fluorescent labels. Two or more of the labels may be excited using a single excitation source, which may be a laser. For example, the excitation bands for the two or more labels may be at least partially overlapping such that excitation in the overlap region of the spectrum
15 causes both labels to emit fluorescence. In particular embodiments, the emission from the two or more labels will occur in different regions of the spectrum such that presence of at least one of the labels can be determined by optically distinguishing the emission.


20

The kit may contain four labelled nucleotides, where the first of four nucleotides is labelled with a compound as disclosed herein. In such a kit, the second, third, and fourth nucleotides can each be labelled with a compound
25 that is optionally different from the label on the first nucleotide and optionally different from the labels on each other. Thus, one or more of the compounds can have a distinct absorbance maximum and/or emission maximum such that the compound(s) is(are) distinguishable from other
30 compounds. For example, each compound can have a distinct absorbance maximum and/or emission maximum such that each of the compounds is distinguishable from the other three compounds. It will be understood that parts of the absorbance spectrum and/or emission spectrum other than


the maxima can differ and these differences can be exploited to distinguish the compounds. The kit may be such that two or more of the compounds have a distinct absorbance maximum above 600 nm. The compounds of the invention typically absorb light in the region above 640 nm.

The compounds, nucleotides or kits that are set forth herein may be used to detect, measure or identify a biological system (including, for example, processes or components thereof). Exemplary techniques that can employ the compounds, nucleotides or kits include sequencing, expression analysis, hybridisation analysis, genetic analysis, RNA analysis, cellular assay (e.g. cell binding or cell function analysis), or protein assay (e.g. protein binding assay or protein activity assay). The use may be on an automated instrument for carrying out a particular technique, such as an automated sequencing instrument. The sequencing instrument may contain two lasers operating at different wavelengths.


Disclosed herein is a method of synthesising compounds of the disclosure. A compound of formula (X) and/or (X1), (X2) (X3) or (X4) or a salt thereof may be used as a starting material for the synthesis of symmetrical or unsymmetrical polymethine dyes:




(X)




(X1)



(X2)



(X3)



(X4)

5


or a salt thereof wherein R_{a1} is H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom; R_{c1} is alkyl or substituted alkyl; Ar is an aromatic

group and R is an alkyl group. Where specific examples of 4-hydroxyphenyl are shown, further hydroxyl groups may also be substituted on the ring in cases where n is greater than one. r can be equal to 3.

5

Disclosed herein is a method of synthesising compounds of the disclosure. A compound of formula (X5) or a salt thereof may be used as a starting material for the synthesis of symmetrical or unsymmetrical polymethine dyes:

10



(X5)

As used herein, the term "alkyl" refers to C₁-C₂₀ hydrocarbon and may include C₃-C₁₀ non-aromatic carbocyclic rings. In particular embodiments the alkyl groups are C₁-C₆ alkyl which refers to saturated, straight- or branched-chain hydrocarbon radicals containing between one and six carbon atoms, respectively. In particular cases, alkyl groups may include one or more unsaturated groups, and thus include alkenyl and alkynyl.

15

20

The term "halogen" as used herein refers to fluoro- (hereafter designated as F), chloro- (hereafter designated as Cl), bromo- (hereafter designated as Br) or iodo-

25

(hereafter designated as I), and usually relates to substitution for a hydrogen atom in an organic compound, this substitution is optionally a full substitution for the hydrogen.

5

The term "substituted alkyl", refers to alkyl, alkenyl or alkynyl groups as defined above where they may optionally be further substituted with, but not limited to, halo, cyano, SO_3^- , SRa , ORa , NRbRc , oxo, CONRbRc , COOH and COORb . Ra , Rb and Rc may be each independently selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl and substituted aryl. Further, said substituted alkyl, substituted alkenyl and substituted alkynyl may optionally be interrupted by at least one hetero atom or group selected from O, NRb , $\text{S}(\text{O})_t$ where t is 0 to 2, and the like. Substituted alkyl also covers group such as benzyl where the alkyl groups is comprises a further aryl or substituted aryl moiety.

20

Dyes according to the present disclosure may be synthesised from a variety of different starting materials, including N-propyl-4-hydroxyphenylether substituted indoles. The dyes may be made symmetrically, such that the same indole is at both end of the polymethine chain, or unsymmetrically such that different indoles are at either end of the chromophore. Methods for preparing polymethine dyes are well known in the art.

30 According to an aspect of the disclosure there are provided dye compounds suitable for attachment to substrate moieties, particularly comprising linker groups to enable attachment to substrate moieties. Substrate moieties can be virtually any molecule or substance to

which the dyes of the disclosure can be conjugated and, by way of non-limiting example, may include nucleosides, nucleotides, polynucleotides, carbohydrates, ligands, particles, solid surfaces, organic and inorganic
5 polymers, chromosomes, nuclei, living cells and combinations or assemblages thereof. The dyes can be conjugated by an optional linker by a variety of means including hydrophobic attraction, ionic attraction and covalent attachment. Particularly the dyes are conjugated
10 to the substrate by covalent attachment. More particularly the covalent attachment is by means of a linker group.


The conjugation of the dye compound to the substrate can
15 be carried out via carboxyl group COX, which can be turned into an amide or ester.


The dyes according to the present disclosure may include a reactive linker group at one of the substituent
20 positions for covalent attachment of the dye to another molecule. Reactive linking groups are moieties capable of forming a bond (e.g. a covalent or non-covalent bond). In a particular embodiment the linker may be a cleavable linker. Use of the term "cleavable linker" is not meant
25 to imply that the whole linker is required to be removed. The cleavage site can be located at a position on the linker that results in part of the linker remaining attached to the dye and/or substrate moiety after cleavage. Cleavable linkers may be, by way of non-
30 limiting example, electrophilically cleavable linkers, enzymatically cleavable linkers, nucleophilically cleavable linkers, photocleavable linkers, cleavable under reductive conditions (for example disulfide or azide containing linkers), oxidative conditions,

cleavable via use of safety-catch linkers and cleavable by elimination mechanisms. The use of a cleavable linker to attach the dye compound to a substrate moiety provides the option of removing the label, for example after
5 detection, thereby avoiding any interfering signal in downstream steps.

Useful linker groups may be found in PCT publication number WO2004/018493 (herein incorporated by reference)
10 examples of which include linkers that, may be cleaved using water-soluble phosphines or water-soluble transition metal catalysts formed from a transition metal and at least partially water-soluble ligands. In aqueous solution the latter form at least partially water-soluble
15 transition metal complexes. Such cleavable linkers can be used to connect bases of nucleotides to labels such as the dyes set forth herein.

Particular linkers may be found in PCT publication number
20 WO2004/018493 (herein incorporated by reference) such as those that include moieties of the formula:





(wherein X is selected from the group comprising O, S, NH
 5 and NQ wherein Q is a C1-10 substituted or unsubstituted
 alkyl group, Y is selected from the group comprising O,
 S, NH and N(allyl), T is hydrogen or a C₁-C₁₀ substituted
 or unsubstituted alkyl group and * indicates where the
 moiety is connected to the remainder of the nucleotide or
 10 nucleoside).

In particular embodiments, the length of the linker
 between a fluorescent dye (fluorophore) and a guanine
 base can be altered, for example, by introducing a
 15 polyethylene glycol spacer group, thereby increasing the
 fluorescence intensity compared to the same fluorophore
 attached to the guanine base through other linkages known
 in the art. Exemplary linkers and their properties are
 set forth in GB patent application number 0517097.2,
 20 published as WO07020457, (herein incorporated by
 reference). The design of linkers, and especially their
 increased length, can allow improvements in the
 brightness of fluorophores attached to the guanine bases
 of guanosine nucleotides when incorporated into
 25 polynucleotides such as DNA. Thus, when the dye is for
 use in any method of analysis which employs detection of
 a fluorescent dye label attached to a guanine-containing
 nucleotide, it can be advantageous to use a linker having
 a spacer group of formula -((CH₂)₂O)_n- wherein n is an

integer between 2 and 50, for example, as described in WO07020457.

The present disclosure further provides conjugates of nucleosides and nucleotides labelled with one or more of the dyes set forth herein (modified nucleotides). Labelled nucleosides and nucleotides are useful for labelling polynucleotides formed by enzymatic synthesis, such as, by way of non-limiting example, in PCR amplification, isothermal amplification, solid phase amplification, polynucleotide sequencing (e.g. solid phase sequencing), nick translation reactions and the like.

Nucleosides and nucleotides may be labelled at sites on the sugar or nucleobase. As known in the art, a "nucleotide" consists of a nitrogenous base, a sugar, and one or more phosphate groups. In RNA the sugar is ribose and in DNA is a deoxyribose, i.e. a sugar lacking a hydroxyl group that is present in ribose. The nitrogenous base is a derivative of purine or pyrimidine. The purines can be adenine (A) or guanine (G), and the pyrimidines can be cytosine (C), thymine (T) or in the context of RNA, uracil (U). The C-1 atom of deoxyribose is bonded to N-1 of a pyrimidine or N-9 of a purine. A nucleotide is also a phosphate ester of a nucleoside, with esterification occurring on the hydroxyl group attached to the C-3 or C-5 of the sugar. Nucleotides are usually mono, di- or triphosphates.

A "nucleoside" is structurally similar to a nucleotide but is missing the phosphate moieties. An example of a nucleoside analog would be one in which the label is

linked to the base and there is no phosphate group attached to the sugar molecule.


Although the base is usually referred to as a purine or pyrimidine, the skilled person will appreciate that derivatives and analogues are available which do not alter the capability of the nucleotide or nucleoside to undergo Watson-Crick base pairing. "Derivative" or "analogue" means a compound or molecule whose core structure is the same as, or closely resembles that of a parent compound but which has a chemical or physical modification, such as, for example, a different or additional side group, which allows the derivative nucleotide or nucleoside to be linked to another molecule. For example, the base may be a deazapurine. In particular embodiments, the derivatives are capable of undergoing Watson-Crick pairing. "Derivative" and "analogue" also include, for example, a synthetic nucleotide or nucleoside derivative having modified base moieties and/or modified sugar moieties. Such derivatives and analogues are discussed in, for example, Scheit, Nucleotide analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90:543-584, 1990. Nucleotide analogues can also have modified phosphodiester linkages including phosphorothioate, phosphorodithioate, alkylphosphonate, phosphoranilidate, phosphoramidate linkages and the like.

A dye may be attached to any position on a nucleotide base, for example, through a linker. In particular embodiments Watson-Crick base pairing can still be carried out for the resulting analogue. Particular nucleobase labelling sites include the C5 position of a pyrimidine base or the C7 position of a 7-deaza purine

base. As described above a linker group may be used to covalently attach a dye to the nucleoside or nucleotide.

In particular embodiments the labelled nucleoside or nucleotide may be enzymatically incorporable and enzymatically extendable. Accordingly a linker moiety may be of sufficient length to connect the nucleotide to the compound such that the compound does not significantly interfere with the overall binding and recognition of the nucleotide by a nucleic acid replication enzyme. Thus, the linker can also comprise a spacer unit. The spacer distances, for example, the nucleotide base from a cleavage site or label.

Nucleosides or nucleotides labelled with dyes of the disclosure may have the formula:



Where Dye is a dye compound according to the present disclosure, B is a nucleobase, such as, for example uracil, thymine, cytosine, adenine, guanine and the like and L is an optional linker group which may or may not be present. R' can be H, monophosphate, diphosphate, triphosphate, thiophosphate, a phosphate ester analog, -O- attached to a reactive phosphorous containing group or -O- protected by a blocking group. R'' can be H, OH, a phosphoramidite or a 3'OH blocking group and R''' is H or OH.

Where R'' is phosphoramidite, R' is an acid-cleavable

hydroxyl protecting group which allows subsequent monomer coupling under automated synthesis conditions.

5 In a particular embodiment the blocking group is separate and independent of the dye compound, i.e. not directly attached to it. In an alternative embodiment the dye may comprise all or part of the 3'OH blocking group. Thus R'' can be a 3'OH blocking group which may or may not comprise a dye compound disclosed herein.

10

In still yet another alternative embodiment there is no blocking group on the 3' carbon of the pentose sugar and the dye (or dye and linker construct) attached to the base, for example, can be of a size or structure
15 sufficient to act as a block to the incorporation of a further nucleotide. Thus the block can be due to steric hindrance or can be due to a combination of size, charge and structure, whether or not the dye is attached to the 3' position of the sugar.

20

In still yet another alternative embodiment the blocking group is present on the 2' or 4' carbon of the pentose sugar and can be of a size or structure sufficient to act as a block to the incorporation of a further nucleotide.

25 The use of a blocking group allows polymerisation to be controlled, such as by stopping extension when a modified nucleotide is incorporated. If the blocking effect is reversible, for example by way of non-limiting example by changing chemical conditions or by removal of a chemical
30 block, extension can be stopped at certain points and then allowed to continue.

In another particular embodiment a 3'OH blocking group will comprise moieties disclosed in WO2004/018497 (herein

incorporated by reference). For example the blocking group may be azidomethyl (CH_2N_3) or allyl.

In a particular embodiment a linker (between dye and nucleotide) and a blocking group are both present and are separate moieties. In particular embodiments the linker and blocking group are both cleavable under substantially similar conditions. Thus deprotection and deblocking processes may be more efficient since only a single treatment will be required to remove both the dye compound and the block. However, in some embodiments a linker and blocking group need not be cleavable under similar conditions, instead being individually cleavable under distinct conditions.

This disclosure also encompasses polynucleotides incorporating dye compounds. Such polynucleotides may be DNA or RNA comprised respectively of deoxyribonucleotides or ribonucleotides joined in phosphodiester linkage. Polynucleotides according to the disclosure may comprise naturally occurring nucleotides, non-naturally occurring (or modified) nucleotides other than the modified nucleotides of the disclosure or any combination thereof, in combination with at least one modified nucleotide (e.g. labelled with a dye compound) set forth herein. Polynucleotides according to the disclosure may also include non-natural backbone linkages and/or non-nucleotide chemical modifications. Chimeric structures comprised of mixtures of ribonucleotides and deoxyribonucleotides comprising at least one modified nucleotide according to the disclosure are also contemplated.

Modified nucleotides (or nucleosides) comprising a dye

compound according to the present disclosure may be used in any method of analysis such as methods that include detection of a fluorescent label attached to a nucleotide or nucleoside, whether on its own or incorporated into or associated with a larger molecular structure or conjugate. In this context the term "incorporated into a polynucleotide" can mean that the 5' phosphate is joined in phosphodiester linkage to the 3' hydroxyl group of a second (modified or unmodified) nucleotide, which may itself form part of a longer polynucleotide chain. The 3' end of a modified nucleotide set forth herein may or may not be joined in phosphodiester linkage to the 5' phosphate of a further (modified or unmodified) nucleotide. Thus, in one non-limiting embodiment the disclosure provides a method of detecting a modified nucleotide incorporated into a polynucleotide which comprises: (a) incorporating at least one modified nucleotide of the disclosure into a polynucleotide and (b) detecting the modified nucleotide(s) incorporated into the polynucleotide by detecting the fluorescent signal from the dye compound attached to said modified nucleotide(s).

This method can include: a synthetic step (a) in which one or more modified nucleotides according to the disclosure are incorporated into a polynucleotide and a detection step (b) in which one or more modified nucleotide(s) incorporated into the polynucleotide are detected by detecting or quantitatively measuring their fluorescence.

In one embodiment of the present disclosure at least one modified nucleotide is incorporated into a polynucleotide in a synthetic step by the action of a polymerase enzyme.

However, other methods of joining modified nucleotides to polynucleotides, such as for example chemical oligonucleotide synthesis or ligation of labelled oligonucleotides to unlabelled oligonucleotides can be used. Therefore, the term "incorporating", when used in reference to a nucleotide and polynucleotide, can encompass polynucleotide synthesis by chemical methods as well as enzymatic methods.

10 In a specific embodiment a synthetic step is carried out and may optionally comprise incubating a template polynucleotide strand with a reaction mixture comprising fluorescently labelled modified nucleotides of the disclosure. A polymerase can also be provided under
15 conditions which permit formation of a phosphodiester linkage between a free 3' hydroxyl group on a polynucleotide strand annealed to the template polynucleotide strand and a 5' phosphate group on the modified nucleotide. Thus, a synthetic step can include
20 formation of a polynucleotide strand as directed by complementary base-pairing of nucleotides to a template strand.

In all embodiments of the method, the detection step may
25 be carried out whilst the polynucleotide strand into which the modified nucleotides are incorporated is annealed to a template strand, or after a denaturation step in which the two strands are separated. Further steps, for example chemical or enzymatic reaction steps
30 or purification steps, may be included between a synthetic step and a detection step. In particular, the target strand incorporating the modified nucleotide(s) may be isolated or purified and then processed further or used in a subsequent analysis. By way of example, target

polynucleotides labelled with modified nucleotide(s) in a synthetic step may be subsequently used as labelled probes or primers. In other embodiments the product of a synthetic step set forth herein may be subject to further reaction steps and, if desired, the product of these subsequent steps can be purified or isolated.

Suitable conditions for a synthetic step will be well known to those familiar with standard molecular biology techniques. In one embodiment a synthetic step may be analogous to a standard primer extension reaction using nucleotide precursors, including modified nucleotides set forth herein, to form an extended target strand complementary to the template strand in the presence of a suitable polymerase enzyme. In other embodiments a synthetic step may itself form part of an amplification reaction producing a labelled double stranded amplification product comprised of annealed complementary strands derived from copying of target and template polynucleotide strands. Other exemplary synthetic steps include nick translation, strand displacement polymerisation, random primed DNA labelling etc. A particularly useful polymerase enzyme for a synthetic step is one that is capable of catalysing the incorporation of one or more of the modified nucleotides set forth herein. A variety of naturally occurring or modified polymerases can be used. By way of example, a thermostable polymerase can be used for a synthetic reaction that is carried out using thermocycling conditions, whereas a thermostable polymerase may not be desired for isothermal primer extension reactions. Suitable thermostable polymerases which are capable of incorporating the modified nucleotides according to the disclosure include those described in WO 2005/024010 or

WO06120433, each of which is incorporated herein by reference. In synthetic reactions which are carried out at lower temperatures such as 37 °C, polymerase enzymes need not necessarily be thermostable polymerases, therefore the choice of polymerase will depend on a number of factors such as reaction temperature, pH, strand-displacing activity and the like.

In specific non-limiting embodiments the disclosure encompasses methods of nucleic acid sequencing, re-sequencing, whole genome sequencing, single nucleotide polymorphism scoring, or any other application involving the detection of the modified nucleotide or nucleoside labelled with dyes set forth herein when incorporated into a polynucleotide. Any of a variety of other applications benefitting from the use of polynucleotides labelled with the modified nucleotides comprising fluorescent dyes can use modified nucleotides or nucleosides labelled with dyes set forth herein.

20

In a particular embodiment the disclosure provides use of modified nucleotides comprising dye compounds according to the disclosure in a polynucleotide sequencing-by-synthesis reaction. Sequencing-by-synthesis generally involves sequential addition of one or more nucleotides or oligonucleotides to a growing polynucleotide chain in the 5' to 3' direction using a polymerase or ligase in order to form an extended polynucleotide chain complementary to the template nucleic acid to be sequenced. The identity of the base present in one or more of the added nucleotide(s) can be determined in a detection or "imaging" step. The identity of the added base may be determined after each nucleotide incorporation step. The sequence of the template may then

30

be inferred using conventional Watson-Crick base-pairing rules. The use of the modified nucleotides labelled with dyes set forth herein for determination of the identity of a single base may be useful, for example, in the
5 scoring of single nucleotide polymorphisms, and such single base extension reactions are within the scope of this disclosure.

In an embodiment of the present disclosure, the sequence
10 of a template polynucleotide is determined by detecting the incorporation of one or more nucleotides into a nascent strand complementary to the template polynucleotide to be sequenced through the detection of fluorescent label(s) attached to the incorporated
15 nucleotide(s). Sequencing of the template polynucleotide can be primed with a suitable primer (or prepared as a hairpin construct which will contain the primer as part of the hairpin), and the nascent chain is extended in a stepwise manner by addition of nucleotides to the 3' end
20 of the primer in a polymerase-catalysed reaction.

In particular embodiments each of the different nucleotide triphosphates (A, T, G and C) may be labelled with a unique fluorophore and also comprises a blocking
25 group at the 3' position to prevent uncontrolled polymerisation. Alternatively one of the four nucleotides may be unlabelled (dark). The polymerase enzyme incorporates a nucleotide into the nascent chain complementary to the template polynucleotide, and the
30 blocking group prevents further incorporation of nucleotides. Any unincorporated nucleotides can be washed away and the fluorescent signal from each incorporated nucleotide can be "read" optically by suitable means, such as a charge-coupled device using laser excitation

and suitable emission filters. The 3'-blocking group and fluorescent dye compounds can then be removed (deprotected), (simultaneously or sequentially) to expose the nascent chain for further nucleotide incorporation.

5 Typically the identity of the incorporated nucleotide will be determined after each incorporation step but this is not strictly essential. Similarly, U.S. Pat. No. 5,302,509 (which is incorporated herein by reference) discloses a method to sequence polynucleotides
10 immobilised on a solid support.

The method, as exemplified above, utilizes the incorporation of fluorescently labelled, 3'-blocked nucleotides A, G, C and T into a growing strand
15 complementary to the immobilised polynucleotide, in the presence of DNA polymerase. The polymerase incorporates a base complementary to the target polynucleotide, but is prevented from further addition by the 3'-blocking group. The label of the incorporated nucleotide can then be
20 determined and the blocking group removed by chemical cleavage to allow further polymerisation to occur. The nucleic acid template to be sequenced in a sequencing-by-synthesis reaction may be any polynucleotide that it is desired to sequence. The nucleic acid template for a
25 sequencing reaction will typically comprise a double stranded region having a free 3' hydroxyl group which serves as a primer or initiation point for the addition of further nucleotides in the sequencing reaction. The region of the template to be sequenced will overhang this
30 free 3' hydroxyl group on the complementary strand. The overhanging region of the template to be sequenced may be single stranded but can be double-stranded, provided that a "nick is present" on the strand complementary to the template strand to be sequenced to provide a free 3' OH

group for initiation of the sequencing reaction. In such
embodiments sequencing may proceed by strand
displacement. In certain embodiments a primer bearing the
free 3' hydroxyl group may be added as a separate
5 component (e.g. a short oligonucleotide) which hybridises
to a single-stranded region of the template to be
sequenced. Alternatively, the primer and the template
strand to be sequenced may each form part of a partially
self-complementary nucleic acid strand capable of forming
10 an intra-molecular duplex, such as for example a hairpin
loop structure. Hairpin polynucleotides and methods by
which they may be attached to solid supports are
disclosed in International application publication nos.
WO0157248 and WO2005/047301, each of which is
15 incorporated herein by reference. Nucleotides can be
added successively to a growing primer, resulting in
synthesis of a polynucleotide chain in the 5' to 3'
direction. The nature of the base which has been added
may be determined, particularly but not necessarily after
20 each nucleotide addition, thus providing sequence
information for the nucleic acid template. Thus, a
nucleotide is incorporated into a nucleic acid strand (or
polynucleotide) by joining of the nucleotide to the free
3' hydroxyl group of the nucleic acid strand via
25 formation of a phosphodiester linkage with the 5'
phosphate group of the nucleotide.

The nucleic acid template to be sequenced may be DNA or
RNA, or even a hybrid molecule comprised of
30 deoxynucleotides and ribonucleotides. The nucleic acid
template may comprise naturally occurring and/or non-
naturally occurring nucleotides and natural or non-
natural backbone linkages, provided that these do not
prevent copying of the template in the sequencing

reaction.

In certain embodiments the nucleic acid template to be sequenced may be attached to a solid support via any suitable linkage method known in the art, for example via covalent attachment. In certain embodiments template polynucleotides may be attached directly to a solid support (e.g. a silica-based support). However, in other embodiments of the disclosure the surface of the solid support may be modified in some way so as to allow either direct covalent attachment of template polynucleotides, or to immobilise the template polynucleotides through a hydrogel or polyelectrolyte multilayer, which may itself be non-covalently attached to the solid support.

Arrays in which polynucleotides have been directly attached to silica-based supports are those for example disclosed in W000006770 (incorporated herein by reference), wherein polynucleotides are immobilised on a glass support by reaction between a pendant epoxide group on the glass with an internal amino group on the polynucleotide. In addition, polynucleotides can be attached to a solid support by reaction of a sulphur-based nucleophile with the solid support, for example, as described in W02005/047301 (incorporated herein by reference). A still further example of solid-supported template polynucleotides is where the template polynucleotides are attached to hydrogel supported upon silica-based or other solid supports, for example, as described in W000/31148, W001/01143, W002/12566, W003/014392, U.S. Pat. No. 6,465,178 and W000/53812, each of which is incorporated herein by reference.

A particular surface to which template polynucleotides

may be immobilised is a polyacrylamide hydrogel. Polyacrylamide hydrogels are described in the references cited above and in WO2005/065814, which is incorporated herein by reference.

5

DNA template molecules can be attached to beads or microparticles, for example as described in U.S. Pat. No. 6,172,218 (which is incorporated herein by reference). Attachment to beads or microparticles can be useful for sequencing applications. Bead libraries can be prepared where each bead contains different DNA sequences. Exemplary libraries and methods for their creation are described in Nature. 437, 376-380 (2005); Science. 309, 5741, 1728-1732 (2005), each of which is incorporated herein by reference. Sequencing of arrays of such beads using nucleotides set forth herein is within the scope of the disclosure.

Template(s) that are to be sequenced may form part of an "array" on a solid support, in which case the array may take any convenient form. Thus, the method of the disclosure is applicable to all types of high density arrays, including single-molecule arrays, clustered arrays and bead arrays. Modified nucleotides labelled with dye compounds of the present disclosure may be used for sequencing templates on essentially any type of array, including but not limited to those formed by immobilisation of nucleic acid molecules on a solid support.

30

However, the modified nucleotides labelled with dye compounds of the disclosure are particularly advantageous in the context of sequencing of clustered arrays. In clustered arrays, distinct regions on the array (often

referred to as sites, or features) comprise multiple polynucleotide template molecules. Generally, the multiple polynucleotide molecules are not individually resolvable by optical means and are instead detected as an ensemble. Depending on how the array is formed, each site on the array may comprise multiple copies of one individual polynucleotide molecule (e.g. the site is homogenous for a particular single- or double-stranded nucleic acid species) or even multiple copies of a small number of different polynucleotide molecules (e.g. multiple copies of two different nucleic acid species). Clustered arrays of nucleic acid molecules may be produced using techniques generally known in the art. By way of example, WO 98/44151 and WO00/18957, each of which is incorporated herein, describe methods of amplification of nucleic acids wherein both the template and amplification products remain immobilised on a solid support in order to form arrays comprised of clusters or "colonies" of immobilised nucleic acid molecules. The nucleic acid molecules present on the clustered arrays prepared according to these methods are suitable templates for sequencing using the modified nucleotides labelled with dye compounds of the disclosure.

The modified nucleotides labelled with dye compounds of the present disclosure are also useful in sequencing of templates on single molecule arrays. The term "single molecule array" or "SMA" as used herein refers to a population of polynucleotide molecules, distributed (or arrayed) over a solid support, wherein the spacing of any individual polynucleotide from all others of the population is such that it is possible to individually resolve the individual polynucleotide molecules. The target nucleic acid molecules immobilised onto the

surface of the solid support can thus be capable of being resolved by optical means in some embodiments. This means that one or more distinct signals, each representing one polynucleotide, will occur within the resolvable area of the particular imaging device used.

Single molecule detection may be achieved wherein the spacing between adjacent polynucleotide molecules on an array is at least 100 nm, more particularly at least 250 nm, still more particularly at least 300 nm, even more particularly at least 350 nm. Thus, each molecule is individually resolvable and detectable as a single molecule fluorescent point, and fluorescence from said single molecule fluorescent point also exhibits single step photobleaching.

The terms "individually resolved" and "individual resolution" are used herein to specify that, when visualised, it is possible to distinguish one molecule on the array from its neighbouring molecules. Separation between individual molecules on the array will be determined, in part, by the particular technique used to resolve the individual molecules. The general features of single molecule arrays will be understood by reference to published applications WO00/06770 and WO 01/57248, each of which is incorporated herein by reference. Although one use of the modified nucleotides of the disclosure is in sequencing-by-synthesis reactions, the utility of the modified nucleotides is not limited to such methods. In fact, the nucleotides may be used advantageously in any sequencing methodology which requires detection of fluorescent labels attached to nucleotides incorporated into a polynucleotide.

In particular, the modified nucleotides labelled with dye compounds of the disclosure may be used in automated fluorescent sequencing protocols, particularly fluorescent dye-terminator cycle sequencing based on the chain termination sequencing method of Sanger and co-workers. Such methods generally use enzymes and cycle sequencing to incorporate fluorescently labelled dideoxynucleotides in a primer extension sequencing reaction. So called Sanger sequencing methods, and related protocols (Sanger-type), utilize randomised chain termination with labelled dideoxynucleotides.

Thus, the present disclosure also encompasses modified nucleotides labelled with dye compounds which are dideoxynucleotides lacking hydroxyl groups at both of the 3' and 2' positions, such modified dideoxynucleotides being suitable for use in Sanger type sequencing methods and the like.

Modified nucleotides labelled with dye compounds of the present disclosure incorporating 3' blocking groups, it will be recognized, may also be of utility in Sanger methods and related protocols since the same effect achieved by using modified dideoxy nucleotides may be achieved by using modified nucleotides having 3'-OH blocking groups: both prevent incorporation of subsequent nucleotides. Where nucleotides according to the present disclosure, and having a 3' blocking group are to be used in Sanger-type sequencing methods it will be appreciated that the dye compounds or detectable labels attached to the nucleotides need not be connected via cleavable linkers, since in each instance where a labelled nucleotide of the disclosure is incorporated; no

nucleotides need to be subsequently incorporated and thus the label need not be removed from the nucleotide.

The present disclosure also provides kits including modified nucleosides and/or nucleotides labelled with dyes. Such kits will generally include at least one modified nucleotide or nucleoside labelled with a dye set forth herein together with at least one further component. The further component(s) may be one or more of the components identified in a method set forth above or in the Examples section below. Some non-limiting examples of components that can be combined into a kit of the present disclosure are set forth below.

In a particular embodiment, a kit can include at least one modified nucleotide or nucleoside labelled with a dye set forth herein together with modified or unmodified nucleotides or nucleosides. For example, modified nucleotides labelled with dyes according to the disclosure may be supplied in combination with unlabelled or native nucleotides, and/or with fluorescently labelled nucleotides or any combination thereof. Accordingly the kits may comprise modified nucleotides labelled with dyes according to the disclosure and modified nucleotides labelled with other, for example, prior art dye compounds. Combinations of nucleotides may be provided as separate individual components (e.g. one nucleotide type per vessel or tube) or as nucleotide mixtures (e.g. two or more nucleotides mixed in the same vessel or tube).

Where kits comprise a plurality, particularly two, more particularly four, modified nucleotides labelled with a dye compound, the different nucleotides may be labelled with different dye compounds, or one may be dark, with no dye compounds. Where the different nucleotides are

labelled with different dye compounds it is a feature of the kits that said dye compounds are spectrally distinguishable fluorescent dyes. As used herein, the term "spectrally distinguishable fluorescent dyes" refers to fluorescent dyes that emit fluorescent energy at wavelengths that can be distinguished by fluorescent detection equipment (for example, a commercial capillary based DNA sequencing platform) when two or more such dyes are present in one sample. When two modified nucleotides labelled with fluorescent dye compounds are supplied in kit form, it is a feature of some embodiments that the spectrally distinguishable fluorescent dyes can be excited at the same wavelength, such as, for example by the same laser. When four modified nucleotides labelled with fluorescent dye compounds are supplied in kit form, it is a feature of some embodiments that two of the spectrally distinguishable fluorescent dyes can both be excited at one wavelength and the other two spectrally distinguishable dyes can both be excited at another wavelength. Particular excitation wavelengths are 532 nm, 630 nm to 700 nm, particularly 660 nm.

In one embodiment a kit includes a modified nucleotide labelled with a compound of the present disclosure and a second modified nucleotide labelled with a second dye wherein the dyes have a difference in absorbance maximum of at least 10 nm, particularly 20 nm to 50 nm. More particularly the two dye compounds have Stokes shifts of between 15-40 nm where "Stokes shift" is the distance between the peak absorption and peak emission wavelengths.

In a further embodiment a kit can further include two other modified nucleotides labelled with fluorescent dyes

wherein the dyes are excited by the same laser at 488 nm to 550 nm, particularly 532 nm. The dyes can have a difference in absorbance maximum of at least 10 nm, particularly 20 nm to 50 nm. More particularly the two dye compounds can have Stokes shifts of between 20-40 nm. Still yet more particularly the two dye compounds can have a different absorbance maximum below 640 nm, particularly below 600 nm. Particular dyes which are spectrally distinguishable from polymethine dyes of the present disclosure and which meet the above criteria are polymethine analogues as described in U.S. Pat. No. 5,268,486 (for example Cy3) or WO 0226891 (Alexa 532; Molecular Probes A20106) or unsymmetrical polymethines as disclosed in U.S. Pat. No. 6,924,372, each of which is incorporated herein by reference. Alternative dyes include rhodamine analogues, for example tetramethyl rhodamine and analogues thereof.

In an alternative embodiment, the kits of the disclosure may contain nucleotides where the same base is labelled with two different compounds. A first nucleotide may be labelled with a compound of the disclosure. A second nucleotide may be labelled with a spectrally distinct compound, for example a 'green' dye absorbing at less than 600 nm. A third nucleotide may be labelled as a mixture of the compound of the disclosure and the spectrally distinct compound, and the fourth nucleotide may be 'dark' and contain no label. In simple terms therefore the nucleotides 1-4 may be labelled 'green', 'red', 'red/green', and dark. To simplify the instrumentation further, four nucleotides can be labelled with a two dyes excited with a single laser, and thus the labelling of nucleotides 1-4 may be 'red 1', 'red 2' 'red

1/red 2', and dark or 'green 1', 'green 2' 'green 1/green 2', and dark.

Nucleotides may contain two dyes of the present disclosure. Dyes where Ra_1 or Ra_2 is a further aromatic ring fused to adjacent carbons of the indole ring absorb at a longer wavelength than where the dyes do not have the further aromatic conjugation. A kit may contain two or more nucleotides labelled with dyes of the disclosure. A kit may contain a nucleotide labelled with a compound of the disclosure where each of Ra_1 and Ra_2 is independently H, SO_3^- , sulphonamide or halogen, and one nucleotide labelled with a compound of the disclosure where one or both Ra_1 and Ra_2 is a further ring fused to an adjacent carbon atom. Kits may contain a further nucleotide where the nucleotide is labelled with a dye that absorbs in the region of 520 nm to 560 nm. Kits may further contain an unlabelled nucleotide.

Nucleotides may contain two dyes of the present disclosure. Dyes where p is one absorb at a shorter wavelength than where p is two. A kit may contain two or more nucleotides labelled with dyes of the disclosure. A kit may contain a nucleotide labelled with a compound of the disclosure where p is one, and one nucleotide labelled with a compound of the disclosure where p is two. Kits may contain a further nucleotide where the nucleotide is labelled with a third label. Kits may further contain an unlabelled nucleotide or a nucleotide labelled with a fourth label.

Although kits are exemplified above in regard to configurations having different nucleotides that are labelled with different dye compounds, it will be


understood that kits can include 2, 3, 4 or more different nucleotides that have the same dye compound.

In particular embodiments a kit may include a polymerase
5 enzyme capable of catalyzing incorporation of the
modified nucleotides into a polynucleotide. Other
components to be included in such kits may include
buffers and the like. The modified nucleotides labelled
with dyes according to the disclosure, and other any
10 nucleotide components including mixtures of different
nucleotides, may be provided in the kit in a concentrated
form to be diluted prior to use. In such embodiments a
suitable dilution buffer may also be included. Again, one
or more of the components identified in a method set
15 forth herein can be included in a kit of the present
disclosure.

It is noted that, as used in this specification and the
appended claims, the singular forms "a", "an" and "the"
20 include plural referents unless expressly and
unequivocally limited to one referent. It will be
apparent to those skilled in the art that various
modifications and variations can be made to various
embodiments described herein without departing from the
25 spirit or scope of the present teachings. Thus, it is
intended that the various embodiments described herein
cover other modifications and variations within the scope
of the appended claims and their equivalents.

Experimental details


Preparation of 4-(3-bromopropoxy)phenol



5 To a solution of hydroquinone (3 g, 27.2 mmol) in methanol (30 mL) was added under N₂ potassium hydroxide (2g, 35.4 mmol) and 1,3-dibromopropane (8.3 mL, 81.7 mmol). The reaction was stirred at 65°C overnight. Then volatiles were removed under vacuum and diethyl ether (30 mL) was added. The organic layer
10 was washed with an ammonium chloride saturated aqueous solution and water (30 mL each). The organic layer was dried with magnesium sulphate, filtered and volatiles were removed under vacuum. The resulting beige slurry was purified by flash chromatography on silica gel (eluent: petroleum ether/ Ethyl
15 Acetate 70/30) providing 2.6g of a white slurry. Yield: 41%. Proton NMR (CDCl₃): 6.87-6.73 (4H, m, H-Ar); 5.36 (1H, s, OH); 4.04 (2H, t, J = 6.2 Hz); 3.60 (2H, J = 6.2 Hz); 2.28 (2H, q, J = 6.2 Hz, H-2). ¹³C NMR (CDCl₃): 152.8, 149.6, 116.1; 116.0; 66.7; 34.4; 30.2.

20


Preparation of 4-(2,3-dimethyl-3H-indol-3-yl)butane-1-sulfonic acid



25 Phenylhydrazine (8.6 mmol, 850 μL) and 5-methyl-6-oxoheptanesulfonic acid (7.2 mmol, 1.5 g) in glacial acetic acid (19 ml) were stirred at 130 °C for 3 hours. The reaction mixture was cooled down to room temperature and the solvent removed under vacuum. The residue was purified by flash chromatography on silica gel (eluent: dichloromethane/
30 methanol 80/20) providing 1.23g of a pale yellow foam. Yield: 61 %. MS (DUIS): E⁻: 280 (M-1); Proton NMR (D₂O): 7.42 (1H, d, J = 7.8Hz, H-4); 7.27 (1H, t, J = 7.8Hz, H-5); 7.24 (1H, d, J = 7.8Hz, H-7); 7.17 (1H, t, J = 7.8Hz, H-6); 2.59 (2H, dd, J = 7.6, 8.9Hz, H-11); 2.21-2.13 (1H, m); 1.88-1.73 (2H, m, H-8);
35 1.52-1.43 (2H, m, H-10); 1.13 (3H, s, CH₃ on C-3); 0.70-0.63 (1H, m, H-9a); 0.51-0.44 (1H, m, H-9b). ¹³C NMR (D₂O): 190.8;


152.3; 143.7; 127.8; 125.7; 122.2; 118.6; 57.9; 50.5; 48.9;
35.6; 24.0; 22.5; 21.8; 14.8.

5 **Preparation of 1-(3-(4-hydroxyphenoxy)propyl)-2,3-dimethyl-3-(4-sulfobutyl)-3H-indol-1-ium**



10 4-(3-bromopropoxy)phenol (1.90 mmol, 438 mg) and of 4-(2,3-dimethyl-3H-indol-3-yl)butane-1-sulfonic acid (1.58 mmol, 504 mg) in sulfolane (2 ml) were stirred at 120 °C for 4.5 h. The reaction mixture was cooled down to room temperature and was directly purified by flash chromatography on silica gel (eluent: dichloromethane/ methanol 65/35) providing 329 mg of a pale grey oil. Yield: 40 %. MS (DUI): E^- : 430 (M-1), E^+ : 432 (M+1); Proton NMR (TFA): 7.75-7.65 (4H, m, H-4/5/6/7); 6.98 (2H, d, J = 8.9 Hz, Har on phenyl); 6.85 (2H, d, J = 8.9 Hz, Har on phenyl); 4.82 (2H, bt, J = 6.6 Hz, H-12); 4.24-4.13 (2H, m, H-14); 3.69 (1H, s); 3.20-3.06 (2H, m, H-11); 2.91 (3H, s, CH₃ on C-2); 2.63-2.52 (2H, m, H-13); 2.41-2.75 (2H, m, H-8); 1.90-1.83 (2H, m, H-10); 1.66 (3H, s, CH₃ on C-3); 1.13-0.93 (2H, m, H-9).

Preparation of 1-(3-(4-hydroxyphenoxy)propyl)-2,3,3-trimethyl-3H-indol-1-ium



25 4-(3-bromopropoxy)phenol (1.40 mmol, 324 mg) and trimethylindolenine (0.80 mmol, 129 μ l) in sulfolane (1 ml) were stirred at 120 °C for 3 hours. The reaction mixture was cooled down to room temperature and was directly purified by flash chromatography on silica gel (eluent: dichloromethane/ methanol 90/10) providing 260 mg of a pale grey oil. Yield: 84 %.


30 Proton NMR (MeOD): 7.06 (1H, d, J = 7.2 Hz, H-4); 7.00 (1H, bt, J = 7.8 Hz, H-5); 6.77-6.64 (5 H, m, H-6 & H-on phenyl ortho & meta); 6.58 (1H, d, J = 7.8 Hz, H-7); 3.90 (2H, t, J =

5.8Hz, H-8), 3.71 (2H, J = 6.5Hz, H-10); 2.04 (2H, bq, J = 6.1Hz, H-9); 1.30 (6H, s, 2xCH₃ on C-3). ¹³C NMR (MeOD): 162.7; 153.6; 152.3; 147.2; 138.6; 128.6; 122.7; 119.5; 116.8; 116.6; 116.5; 103.3; 66.8; 45.1; 39.7; 30.6; 27.5.

5

Preparation of AF670POPO

Product synthesis scheme:




10 Dye synthesis procedure:

4-(2,3-dimethyl-3H-indol-3-yl)butane-1-sulfonic acid (204 mg, 400 μmol) and malonaldehyde Bis(phenylimine) monohydrochloride (114 mg, 440 μmol) were stirred in mixture of acetic anhydride/acetic acid (2/0.6 ml) at 100 °C for 1.5 h.

15 Potassium acetate (118 mg, 1.20 mmol) and the sulfonated benzindolium salt X (193 mg, 400 μmol) were added. The reaction mixture was stirred at 100 °C for 3 h. Then it was cooled down to room temperature and diethyl ether (40 mL) was added. A dark blue solid crashed out. It was filtered, washed with extra diethyl ether (40 mL) and dissolved in water (25 mL) containing ~30 % of acetonitrile. The resulting dark blue solution was filtered and purified by preparative HPLC. The main blue coloured (absorption max ~ 665 nm) fractions were collected and solvents removed in vacuum. MS (DUIS): E⁻: 869 (M-1), 434.1 (M-2/2).

Dyes DX-DX were prepared similarly using appropriate starting materials

30 In Table 1 spectral properties of some dyes prepared in this way (solutions in water, OD ~ 0.2) compared with similar parameters of known structural analogue dye Std (Patent: P6240WO)




Dye	R ₁	R ₂	Max. Abs. (nm)	Max. Fluorescence (nm)
Std (NR650C5)	Ph	SO ₂ NH ₂	650	673
AF670POPO	-(CH ₂) ₃ -O-C ₆ H ₄ - <i>p</i> OH	-Benz-SO ₃ ⁻	666	684
AF670POP	-(CH ₂) ₃ -O-C ₆ H ₅	-Benz-SO ₃	665	684
AF670PPO	-(CH ₂) ₃ -C ₆ H ₄ - <i>p</i> OH	-Benz-SO ₃	665	683
AF670PPOM	-(CH ₂) ₃ -C ₆ H ₄ - <i>p</i> OMe	-Benz-SO ₃	665	683
AF670PP	-(CH ₂) ₃ -C ₆ H ₅	-Benz-SO ₃	664	683

Table 1

Preparation of AF550POPOS0

5 Product synthesis scheme:




Dye synthesis procedure:

- 10 1-(3-(4-hydroxyphenoxy)propyl)-2,3,3-trimethyl-3H-indol-1-ium (150 mg, 385 μmol) and *N,N'*-diphenylformamidine (74 mg, 385 μmol) were stirred in acetic anhydride (2 mL) at 80 °C for 2 h. Acetic acid (0.5 mL), Potassium acetate (567 mg, 5.78 mmol) and the sulfonated indolium salt X (166 mg, 385 μmol) were
- 15 added. The reaction mixture was stirred at 80 °C for 2.5 h. Then volatiles were removed under reduced pressure and diethyl

ether (20 mL) was added. A dark red solid crashed out. It was filtered, washed with extra diethyl ether (20 mL) and dissolved in water (15 mL) containing ~5 % of acetonitrile. The resulting dark red solution was filtered and purified by preparative HPLC. The main red coloured (absorption max ~ 550 nm) fractions were collected and solvents removed in vacuum. MS (DUI): Non-acetylated E⁻: 671.0 (M-1); E⁺: 673.3 (M+1), 774.4 (Et₃N⁺ salt).

10 In Table 2 spectral properties of some dyes prepared in this way (solutions in water, OD ~ 0.2) compared with similar parameters of known structural analogue dyes (Patent: P6240WO)




Dye	R ₁	Max. Abs. (nm)	Max. Fluorescence (nm)
Std 1 (NR550S0)	Ph	550	576
Std 2 (NR545S0)	Me	545	559
AF550POPOS0	-(CH ₂) ₃ -O-C ₆ H ₄ - <i>p</i> OH	548	563
AF550POPS0	-(CH ₂) ₃ -O-C ₆ H ₅	547	566
AF550PPOS0	-(CH ₂) ₃ -C ₆ H ₄ - <i>p</i> OH	548	567
AF550PPS0	-(CH ₂) ₃ -C ₆ H ₅	548	567


Table 2

15

Dye AF670POPO nucleotide conjugate (FFA-AF670POPO)



Anhydrous DMA (3 mL), TSTU (18 mg, 58.8 μmol) and Hunig's Base (0.05 mL) were added to the dried sample of the dye AF670POPO (60 mg, 53.5 μmol). The blue colour of activated ester developed. The reaction mixture was stirred at room temperature for 30 min. According to TLC (20% H₂O in CH₃CN) the activation was completed. After activation was completed, the solution of 5 pppA-LN3 as a triethylammonium salt (53 mg, 56.1 μmol) in DMA/water (0.5/0.3 mL) was added to the reaction. The reaction mixture was stirred at room temperature under nitrogen atmosphere for 18 h. The coupling progress was checked by TLC (20% H₂O in acetonitrile). The reaction mixture was cooled down to $\sim 4^\circ\text{C}$ with an ice-bath, then a 10 solution of 0.1 M TEAB (5 mL) in water was added and the mixture was stirred at room temperature for 10 min. The reaction mixture was applied to column with ~ 25 g of DEAE Sephadex resin suspension in 0.05 M TEAB solution in water and washed with TEAB (concentration gradient from 0.1 M up to 1 M). Coloured fractions were collected and evaporated then co-evaporated again with water to remove more TEAB and vac down to dryness. The residue was then re-dissolved in TEAB 0.1 M. This solution was filtered through a syringe filter 0.2 μm pore size into a corning 20 flask. The product was purified by HPLC using C18 reverse phase column with acetonitrile-0.1 M TEAB. Yield 74 % (based on optical density of solution using estimated extinction coefficient).

Dye AF550POPOS0 nucleotide conjugate (FFT-AF550POPOS0)

Anhydrous DMA (3 mL), TSTU (19 mg, 63.5 μ mol) and Hunig's Base (0.05 mL) were added to the dried sample of the dye AF550POPOS0 (39 mg, 57.7 μ mol). The red colour of activated ester developed. The reaction mixture was stirred at room temperature for 30 min. The solution of pppT-LN3 as a triethylammonium salt (59 mg, 63.5 μ mol) in DMA/water (0.5/0.3 mL) was added to the reaction. The reaction mixture was stirred at room temperature under nitrogen atmosphere for 18 h. The coupling progress was checked by TLC (20% H₂O in acetonitrile). The reaction mixture was cooled down to ~4 °C with an ice-bath, then a 10 solution of 0.1 M TEAB (5 mL) in water was added and the mixture was stirred at room temperature for 10 min. The reaction mixture was applied to column with ~ 25 g of DEAE Sephadex resin suspension in 0.05 M TEAB solution in water and washed with TEAB (concentration gradient from 0.1 M up to 1 M). Coloured fractions were collected and evaporated then co-evaporated again with water to remove more TEAB and vac down to dryness. The residue was then re-dissolved in TEAB 0.1 M. This solution was filtered through a syringe filter 0.2 nm pore size into a corning 20 flask. The product was purified by HPLC using C18 reverse phase column with acetonitrile-0.1 M TEAB. Yield 48 % (based on optical density of solution using estimated extinction coefficient).

Description of figures

Figure 1 FFAs labelled with AF670POPO and its analogues along with ffA-NR650C5 were tested on modified Illumina HiSeqX sequencing systems, in which increasing excitation power of both lasers (red and green) by ca. 33% was deployed at cycle

101 & 251 for read 1 & 2 respectively (see signals on Figure 1).

Figure 2 Unexpectedly, in the case of ffA-NR650C5 (Figure 2), it was observed that the red signals didn't respond proportionally to the power change of red laser. Consequentially, the shape of the base separation scatterplots was altered at cycle 101. The top right circle is closer to the top left circle, meaning it is more difficult to distinguish between the respective labels. The occurring phenomena indicated that NR650C5 was probably photo-saturated or near-saturated at the maximum power density used on HiSeqX. This scatter plot change negatively impacts sequencing quality. Interestingly, with AF670POPO and its analogues, a remarkable improvement was observed. Their signal was increased proportionally with laser power density change. The scatter plot maintained their separations and shape from cycle 100 to cycle 101 when maximum power was deployed (Figure 2). The top right circle in figure 2 is further from the top left circle than the top right circle in figure 1. Thus the labels are better separated in figure 2.


Figure 3 On the 550nm analogues, it was interesting to observe that the presence of hydroxyl on the phenyl ring has a detrimental impact on the fluorescence intensity (figure 3). The fluorescence of AF550POPS0 without the phenolic OH was 3 times stronger than the AF550POPOS0 having the OH.

Figure 4 These new analogues offered opportunities to modulate and optimise scatterplot distribution for sequencing applications. For example, when T was labelled with AF550POPOS0 and A with a mixture of AF670POPO and NR550S0, a nice square scatterplot was achieved (Figure 4a). Furtherly replacing NR550S0 with AF550POPS0 for the green A showed a nicely square scatterplot (Figure 4b).

Figure 5 Based on these new properties, ffT-LN3-AF550POPOS0 and ffA-LN3-AF670POPO were employed to sequence a human template on a modified HiSeqX. A high quality 2x150bp sequencing were achieved < 1% error rate for read 1 and < 1.5% error rate for read 2 (main sequencing metrics shown on figure 5). The scatter plots obtained using the prior art labels meant that a 2x150bp read could not be completed.

Claims:

1. A compound of the formula (I) or mesomeric forms thereof:



5

(I)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

10 p is an integer 1-2;

q is an integer 1-5;

alk is a chain of 1-5 carbon atoms optionally containing one or more double or triple bonds;

Y is S, O or CH₂;

15 Z is OH;

n is an integer 0-3;

X is OH or O⁻ or an amide or ester conjugate thereof;

each of Ra₁ and Ra₂ is independently H, SO₃⁻,


20 sulfonamide, halogen, or a further ring fused to an adjacent carbon atom; and

each of Rc₁ and Rc₂ is independently alkyl or substituted alkyl, wherein at least one of Ra₁ or Ra₂ is SO₃⁻, or Ra₁ or Ra₂ is a further ring fused to

an adjacent carbon atom, the further ring having an SO_3^- , or Rc_1 or Rc_2 is an alkyl sulfonic acid group.

2. A compound according to claim 1 wherein where n is
5 0, Y is S or O.
3. A compound according to claim 1 or claim 2 wherein
(alk) is $(\text{CH}_2)_3$.
4. A compound according to any one of claims 1 to 3
wherein p is 1.
- 10 5. A compound according to any one of claims 1 to 3
wherein p is 2.
6. A compound according to any one of claims 1 to 5
wherein Ra_1 is H or SO_3^- .
7. A compound according to any one of claims 1 to 5
15 wherein Ra_2 is H or SO_3^- .
8. A compound according to any one of claims 1 to 5
wherein Ra_1 is a further ring fused to an adjacent
carbon atom.
9. A compound according to any one of claims 1 to 5
20 wherein Ra_2 is a further ring fused to an adjacent
carbon atom.
10. A compound according to any one preceding claim
wherein Rc_1 or Rc_2 is methyl, ethyl, propyl or -
 $(\text{CH}_2)_t\text{SO}_3^-$ where t is 1-6.
- 25 11. A compound according to claim 10 wherein either Rc_1
or Rc_2 is $(\text{CH}_2)_4\text{-SO}_3^-$.
12. A compound according to any one preceding claim
wherein Y is O.
13. A compound according to any one preceding claim
30 wherein n is 0.
14. A compound according to any one preceding claim
wherein n is 1.
15. A compound according to claim 14 wherein the OH
group is in the 4-position.


16. A compound according to any preceding claim wherein either indole is part of a structure:



- 5 where R_d can be H, alkyl, substituted alkyl, aryl, substituted aryl, halogen, carboxy, sulphonamide, or sulfonic acid.

wherein R_{c1} is alkyl or substituted alkyl.

17. A compound according to claim 1 which is represented by formula (VIIIa):



(VIIIa)

wherein $mCat^+$ or mAn^- is an organic or inorganic positively/negatively charged counterion and


15 m is an integer 0-3;

q is an integer 1-5;

r is an integer 1-5; and

X is OH or O^- or an amide or ester conjugate thereof.

18. A compound according to claim 1 which is represented by formula (VIId):



(VIId)

wherein mCat⁺ or mAn⁻ is an organic or inorganic positively/negatively charged counterion and

m is an integer 0-3;

q is an integer 1-5;

r is an integer 1-5;

t is an integer 1-6; and

X is OH or O⁻ or an amide or ester conjugate thereof.

19. A compound according to any preceding claim wherein the compound is attached to a nucleotide or oligonucleotide.

20. A nucleotide or oligonucleotide labelled with a compound according to claims 1-18.

21. A labelled nucleotide or oligonucleotide according to claim 18 wherein the label is attached via an amide linkage formed from the C(=O)-X moiety.


22. A labelled nucleotide or oligonucleotide according to claims 20 or 21 wherein the label is attached to the C5 position of a pyrimidine base or the C7 position of a 7-deaza purine base through a linker moiety.

23. A labelled nucleotide or oligonucleotide according to any one of claims 20-22, further comprising a 3' OH blocking group covalently attached to the ribose or deoxyribose sugar of the nucleotide.
- 5 24. A kit comprising two or more nucleotides wherein at least one nucleotide is a labelled nucleotide according to claims 20-23.
25. A kit according to claim 24 wherein two of the labelled nucleotides are excited using a single
10 laser.
26. A kit according to claim 25 wherein a first of four nucleotides is a labelled nucleotide according to claims 20-23 and the second, third, and fourth nucleotides are each labelled with a different
15 compound, wherein each compound has a distinct absorbance maximum and each of the compounds is distinguishable from the other three compounds.
27. A kit according to claim 24 comprising four nucleotides wherein a first of the four nucleotides
20 is a labelled nucleotide according to claims 20-23, a second of the four nucleotides is a labelled nucleotide according to claims 20-23, a third nucleotide carries a third label and a fourth nucleotide is unlabelled (dark).
- 25 28. A kit according to claim 24 comprising four nucleotides wherein a first of the four nucleotides is a labelled nucleotide according to claims 20-23, a second of the four nucleotides is a labelled nucleotide according to claims 20-23, a third
30 nucleotide carries a mixture of two labels and a fourth nucleotide is unlabelled (dark).
29. Use of a nucleotide according to any one of claims 20-23, an oligonucleotide according to claims 20-23 or a kit according to any one of claims 24-28 in


sequencing, expression analysis, hybridisation analysis, genetic analysis, RNA analysis or protein binding assays.

30. Use according to claim 29 on an automated sequencing instrument wherein said automated sequencing instrument comprises two lasers operating at different wavelengths.


31. A method of synthesising a compound according to claims 1-18 utilising one of the following starting materials:




(X)




(X1)



(X2)



(X3)




(X4)

or a salt thereof wherein Ra_1 is H, SO_3^- , sulfonamide, halogen, or a further ring fused to an adjacent carbon atom; Rc_1 is alkyl or substituted alkyl; Ar is an aromatic group and R is an alkyl group.

5

32. A method of synthesising a compound according to claims 1-18 utilising the following starting material:



10




Figure 1




Figure 2




Figure 3




Figure 4

|

Lane	Clusters PF (%)	Phas/Prephas R1	% >= Q30 R1	Aligned R1	Error Rate (%) R1	Phas/Prephas R2	% >= Q30 R2	Aligned R2	Error Rate (%) R2
350bp- Human	72.32 ± 3.79	0.151 / 0.132	88.7	95.07 ± 1.46	0.92 ± 0.16	0.141 / 0.140	81.5	93.09 ± 1.64	1.46 ± 0.19

Figure 5

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2016/052986

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D403/06 C07D209/08 C09B23/02 C09B23/06 G01N33/00 G01N33/533 ADD. According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D C09B G01N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data														
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category*</th> <th style="width: 70%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width: 20%;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>WO 2014/135221 A1 (ILLUMINA CAMBRIDGE LTD [GB]) 12 September 2014 (2014-09-12) the whole document claims 1,7,11,15,17 -----</td> <td style="text-align: center; vertical-align: top;">1-32</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A,P</td> <td>WO 2015/170102 A1 (ILLUMINA CAMBRIDGE LTD [GB]) 12 November 2015 (2015-11-12) the whole document claims 1,12,16,20,22 -----</td> <td style="text-align: center; vertical-align: top;">1-32</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>US 5 486 616 A (WAGGONER ALAN S [US] ET AL) 23 January 1996 (1996-01-23) the whole document examples 1-5 ----- -/-</td> <td style="text-align: center; vertical-align: top;">1-32</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	WO 2014/135221 A1 (ILLUMINA CAMBRIDGE LTD [GB]) 12 September 2014 (2014-09-12) the whole document claims 1,7,11,15,17 -----	1-32	A,P	WO 2015/170102 A1 (ILLUMINA CAMBRIDGE LTD [GB]) 12 November 2015 (2015-11-12) the whole document claims 1,12,16,20,22 -----	1-32	A	US 5 486 616 A (WAGGONER ALAN S [US] ET AL) 23 January 1996 (1996-01-23) the whole document examples 1-5 ----- -/-	1-32
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A	WO 2014/135221 A1 (ILLUMINA CAMBRIDGE LTD [GB]) 12 September 2014 (2014-09-12) the whole document claims 1,7,11,15,17 -----	1-32												
A,P	WO 2015/170102 A1 (ILLUMINA CAMBRIDGE LTD [GB]) 12 November 2015 (2015-11-12) the whole document claims 1,12,16,20,22 -----	1-32												
A	US 5 486 616 A (WAGGONER ALAN S [US] ET AL) 23 January 1996 (1996-01-23) the whole document examples 1-5 ----- -/-	1-32												
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.														
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family														
Date of the actual completion of the international search 8 December 2016		Date of mailing of the international search report 14/12/2016												
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Goss, Ilaria												

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2016/052986

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 839 265 A (OHNO SHIGERU [JP] ET AL) 13 June 1989 (1989-06-13) the whole document Dye compounds I-1, I-5, I-7 to I-19, I-21 to I-30	1-32
A	----- WO 2007/020457 A2 (SOLEXA LTD [GB]; LIU XIAOHAI [GB]; MILTON JOHN [GB]) 22 February 2007 (2007-02-22) cited in the application the whole document -----	1-32

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2016/052986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014135221 A1	12-09-2014	AU 2013380645 A1	08-10-2015
		CA 2902982 A1	12-09-2014
		CN 105164106 A	16-12-2015
		EP 2964612 A1	13-01-2016
		WO 2014135221 A1	12-09-2014
WO 2015170102 A1	12-11-2015	AU 2015257477 A1	17-11-2016
		TW 201605796 A	16-02-2016
		US 2015322266 A1	12-11-2015
		US 2016177388 A1	23-06-2016
		WO 2015170102 A1	12-11-2015
US 5486616 A	23-01-1996	US 5268486 A	07-12-1993
		US 5486616 A	23-01-1996
		US 5569766 A	29-10-1996
US 4839265 A	13-06-1989	CA 1318808 C	08-06-1993
		JP H0555056 B2	16-08-1993
		JP S62123454 A	04-06-1987
		US 4839265 A	13-06-1989
		US 5106990 A	21-04-1992
WO 2007020457 A2	22-02-2007	EP 1926829 A2	04-06-2008
		US 2007042407 A1	22-02-2007
		US 2010068722 A1	18-03-2010
		US 2011020827 A1	27-01-2011
		WO 2007020457 A2	22-02-2007